Mosaic ImmunoEngineering (CPMV) EBIT (2010 - 2026)
Mosaic ImmunoEngineering (CPMV) posted quarterly EBIT of -$154802.0 for Q1 2026, up 11.43% year-over-year from -$138926.4 in Q1 2025, and down 4.5% quarter-over-quarter from -$148133.0 in Q4 2025.
Mosaic ImmunoEngineering (CPMV) EBIT (2010 - 2026) Analysis & Trends
Mosaic ImmunoEngineering's EBIT history runs 17 years deep, the most recent figure standing at -$154802.0 for Q1 2026.
- In Q1 2026, EBIT rose 11.43% year-over-year to -$154802.0; the TTM figure through Mar 2026 stood at -$596147.0 (up 24.12% YoY), while the FY2025 annual figure was -$616119.0, up 29.96% from the prior year.
- EBIT for Q1 2026 stood at -$154802.0, down from -$148133.0 in the prior quarter.
- The five-year high for EBIT was -$144358.0 in Q3 2025, with the low at -$883726.0 in Q2 2022.
- The 5-year median for EBIT is -$274302.0 (2024), against an average of -$333992.1.
- The sharpest annual moves came in 2023 and 2025: EBIT jumped 60.11% in 2023, then increased 1.35% in 2025.
- Mosaic ImmunoEngineering's EBIT stood at -$497554.0 in 2022, then surged by 44.61% to -$275618.0 in 2023, then jumped by 45.52% to -$150157.0 in 2024, then increased by 1.35% to -$148133.0 in 2025, then declined by 4.5% to -$154802.0 in 2026.
- Business Quant data shows CPMV's EBIT at -$154802.0 in Q1 2026, -$148133.0 in Q4 2025, and -$144358.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 133.12 Mn |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - | -154,802.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -154,802.00 |
| Dec 31, 2025 | -148,133.00 |
| Sep 30, 2025 | -144,358.00 |
| Jun 30, 2025 | -148,854.00 |
| Mar 31, 2025 | -174,774.00 |
| Dec 31, 2024 | -150,157.00 |
| Sep 30, 2024 | -186,430.00 |
| Jun 30, 2024 | -274,302.00 |
| Mar 31, 2024 | -268,766.00 |
| Dec 31, 2023 | -275,618.00 |
| Sep 30, 2023 | -311,871.00 |
| Jun 30, 2023 | -352,506.00 |
| Mar 31, 2023 | -459,773.00 |
| Dec 31, 2022 | -497,554.00 |
| Sep 30, 2022 | -517,206.00 |
| Jun 30, 2022 | -883,726.00 |
| Mar 31, 2022 | -729,036.00 |
| Dec 31, 2021 | -824,959.00 |
| Sep 30, 2021 | -961,057.00 |
| Jun 30, 2021 | -979,424.00 |